MRVI Q4 2021 Earnings — Maravai LifeSciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

MRVIMaravai LifeSciences Holdings, Inc.

$999M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$228M+132.3% YoY

Gross Profit

$188M82.2% margin

Operating Income

$151M66.1% margin

Net Income

$55M24.3% margin

EPS (Diluted)

$0.42

QoQ Revenue Growth

+11.5%

Cash Flow

Operating Cash Flow

$58M

Free Cash Flow

$53M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$1.9B

Total Liabilities

$1.4B

Stockholders' Equity

$315M

Cash & Equivalents

$551M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$228M	$98M	+132.3%
Gross Profit	$188M	$75M	+150.6%
Operating Income	$151M	$31M	+383.5%
Net Income	$55M	$13M	+322.4%

Revenue Segments

Nucleic Acid Production Segment

$213M93%

Biologics Safety Testing Segment

$16M7%